Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects

Area of Science:

• Immunology
• Neuroimmunology
• Gastroenterology

Background:

• Multiple Sclerosis (MS) involves immune system dysregulation affecting the central nervous system.
• Understanding immune cell activation and gut barrier status in MS is crucial for therapeutic development.
• Previous research has not fully elucidated the impact of different MS therapies on specific immune markers.

Purpose of the Study:

• To analyze gut barrier status, monocyte, and T lymphocyte activation, including regulatory T (Treg) cells in MS patients.
• To compare the differential effects of interferon beta (IFN-β), glatiramer acetate (GA), and natalizumab on these immune parameters.
• To assess immune changes before and after therapy in MS patients.

Main Methods:

• Analysis of serum concentrations of intestinal fatty acid binding protein for gut barrier status.
• Quantification of monocyte markers (soluble CD14, soluble CD163, interleukin 6) and T lymphocyte activation (CD4+DR+, CD8+DR+).
• Flow cytometry analysis of regulatory T cells (CD4+CD25highFoxP3+) in untreated MS patients, patients undergoing therapy, and healthy controls.

Main Results:

• Gut barrier status was comparable between MS patients and healthy controls.
• Untreated MS patients showed elevated soluble CD14 levels and increased activated T lymphocytes and Treg cells at baseline.
• Six months of IFN-β, GA, or natalizumab therapy led to a significant decrease in activated T lymphocytes and Treg percentages, with comparable effects across treatments.

Conclusions:

• MS patients present with a baseline immune state of monocyte and lymphocyte activation, independent of gut barrier integrity.
• An increase in Treg cells correlates with activated T CD8+ lymphocytes in MS patients.
• IFN-β, GA, and natalizumab therapies demonstrate comparable efficacy in reducing immune cell activation and Treg levels in MS.